Our results suggested that the administration of gintonin reduced Aβ pathology, which may be partly due to reduction of oxidant stress [42] and inhibition of p-NF-κB and TNF-α [43], all of which have been indicated to induce neuroinflammation and AD-like pathological changes in neurodegenerative conditions. Here, NFKB1 is linked to Alzheimer disease.